Pfizer/Lilly non-opioid pain drug shows more positive results

Results from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can be effective in osteoarthritis in higher doses, but lower doses remain ineffective and the drug had more adverse safety events than its comparators. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee.
The tanezumab 5 mg treatment arm met two of the three co-primary efficacy endpoints, demonstrating a statistically significant improvement in pain and physical function compared to NSAIDs at the 16-week analysis, while patients’ overall assessment of their OA was not statistically different than NSAIDs.